Overcoming castration resistance in prostate cancer

Current Opinion in Urology

Volumn 22, Issue 3, 2012, Pages 167-174

  Tsao, Che Kai ^a   Small, Alexander C ^a   Galsky, Matthew D ^a   Oh, William K ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

androgen deprivation; androgen receptor; castration resistance; hormone refractory; novel endocrine therapies; prostate cancer

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; APOPTONE; ARN 509; COU 301; DEGARELIX; DOCETAXEL; EPLERENONE; GALETERONE; HE 3235; HYDROCORTISONE; KETOCONAZOLE; LEUPRORELIN; ORTERONEL; PANOBINOSTAT; PRASTERONE; PREDNISONE; TESTOSTERONE; UNCLASSIFIED DRUG; VORINOSTAT;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG BINDING; DRUG DOSE INCREASE; DRUG MEGADOSE; EPIGENETICS; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CASTRATION; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; LIGANDS; MALE; MUTATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

EID: 84859627163     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3283523b8b     Document Type: Review

References (73)

1. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int 2005; 95:1327-1335. (Pubitemid 40799455)
2. Walsh PC, DeWeese TL, Eisenberger MA. A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. J Urol 2001; 166:508-515; discussion 15-16.
3. Cereceda LE, Flechon A, Droz JP. Management of vertebral metastases in prostate cancer: a retrospective analysis in 119 patients. Clin Prostate Cancer 2003; 2:34-40. (Pubitemid 37012419)
4. Thompson IM, Zeidman EJ, Rodriguez FR. Sudden-death due to disease flare with luteinizing-hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990; 144:1479-1480.
5. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. N Engl J Med 1991; 324:93-103.
6. Gittelman M, Pommerville PJ, Persson BE, et al. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008; 180:1986-1992.
7. Van Poppel H, Tombal B, de la Rosette JJ, et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker - results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008; 54:805-813.
8. Tombal B, Miller K, Boccon-Gibod L, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010; 57:836-842.
9. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 2004; 10:7121-7126. (Pubitemid 39487695)
10. Hamada A, Sissung T, Price DK, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008; 14:3312-3318.
11. Bhanalaph T, Varkarakis MJ, Murphy GP. Current status of bilateral adrenalectomy or advanced prostatic carcinoma. Ann Surg 1974; 179:17-23.
12. Witjes FJ, Debruyne FM, Fernandez del Moral P, Geboers AD. Ketoconazole high dose in management of hormonally pretreated patients with progressive metastatic prostate cancer. Dutch South-Eastern Urological Cooperative Group. Urology 1989; 33:411-415. (Pubitemid 19135644)
13. Eil C. Ketoconazole binds to the human androgen receptor. Horm Metab Res 1992; 24:367-370.
14. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22:1025-1033. (Pubitemid 41095034)
15. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26:4563-4571.
16. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27:3742-3748.
17. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28:1496-1501.
18. De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005. This is the first randomized, phase III study that showed the inhibition of androgen biosynthesis by abiraterone and prednisone prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy, providing proof of principal that overcoming castration resistance is possible.
19. Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011; 17:5913-5925. This preclinical study showed that in human CRPC xenographs, abiraterone reduces CRPC growth via suppression of intratumoral androgen, and mechanisms of resistance may include CYP17A1 upregulation or induction of AR and ARsv that confer ligand-independent AR transactivation.
20. Kaku T, Hitaka T, Ojida A, et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 2011; 19:6383-6399.
21. Dreicer R, Agus DB, MacVicar GR,et al. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: A phase I/II, open-label study. In: 2010 ASCO Genitourinary Cancers Symposium San Francisco, California, USA; 2010. This early phase study suggested efficacy and tolerability of TAK-700 therapy in patients with metastatic CRPC.
22. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362:1192-1202.
23. Andriole GL, Humphrey P, Ray P, et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004; 172:915-919. (Pubitemid 39096422)
24. Sartor O, Nakabayashi M, Taplin ME, et al. Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin Genitourin Cancer 2009; 7:E90-E92.
25. Taplin ME, Regan MM, Ko YJ, et al. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15:7099-7105.
26. Chang KH, Li R, Papari-Zareei M, et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci USA 2011; 108:13728-13733. This study showed that the dominant route of DHT synthesis in CRPC bypasses testosterone, and reframes the fundamental metabolic pathway that drives CRPC progression.
27. Yang M, Xie W, Mostaghel E, et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2011; 29:2565-2573.
28. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25:276-308. (Pubitemid 38501396)
29. Migliaccio A, Castoria G, Di Domenico M, et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J 2000; 19:5406-5417.
30. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001; 104:719-730. (Pubitemid 32241022)
31. Castoria G, Lombardi M, Barone MV, et al. Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. J Cell Biol 2003; 161:547-556. (Pubitemid 36578579)
32. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001; 93:1687-1697. (Pubitemid 33130257)
33. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1:34-45. (Pubitemid 33741879)
34. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57:314-319. (Pubitemid 27036612)
35. Kawata H, Ishikura N, Watanabe M, et al. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 2010; 70:745-754.
36. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003; 91:455-461. (Pubitemid 36359626)
37. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787-790.
38. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437-1446. This early phase study suggested efficacy and tolerability of MDV3100 therapy in patients with metastatic CRPC.
39. Sawyers CL. New insights into the prostate cancer genome and therapeutic implications. In: Proceedings of the Prostate Cancer Foundation Annual Scientific Retreat; 15-16 September 2010; Washington DC; 2010.
40. Ahlem C, Kennedy M, Page T, et al. 17alpha-Alkynyl 3alpha, 17beta-androstanediol nonclinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs 2012; 30:59-78.
41. Montgomery B, Morris M, Ryan C,et al. Results of preclinical and clinical phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in castrate-resistant prostate cancer. In: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. Boston, Massachusetts; 2009.
42. Montgomery RB, Morris MJ, Ryan CJ, et al. HE3235, a synthetic adrenal hormone, in patients with castration-resistant prostate cancer (CRPC): Clinical phase I/II trial results. In: 2010 ASCO Genitourinary Cancers Symposium. San Francisco, California; 2010.
43. Harbor BioSciences Inc. Harbor BioSciences Apoptone1 for prostate cancer shows a partial overall response-new positive phase I/IIa data. San Diego, California, USA Harbor BioSciences, Inc; 2010.
44. Montgomery RB. MET. ARMOR1: Phase 1/2, open label, dose escalation, selected dose comparison trial of TOK-001 for the treatment of chemotherapy naive castration resistant prostate cancer. Tokai Pharmaceuticals; 2010.
45. Kelly WK. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol 1998; 34 (Suppl. 3):18-23. (Pubitemid 28499496)
46. Culig Z, Hoffmann J, Erdel M, et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999; 81:242-251. (Pubitemid 29423702)
47. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11:1566-1572. (Pubitemid 23228264)
48. Zhao XY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000; 6:703-706. (Pubitemid 30398797)
49. Culig Z, Klocker H, Eberle J, et al. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 1993; 22:11-22. (Pubitemid 23075489)
50. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998; 152:1-9. (Pubitemid 28028039)
51. Fenton MA, Shuster TD, Fertig AM, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997; 3:1383-1388. (Pubitemid 27362400)
52. Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68:5469-5477.
53. Guo ZY, Yang X, Sun F, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69:2305-2313.
54. Watson PA, Chen YNF, Balbas MD, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010; 107:16759-16765. This preclinical study demonstrated that constitutively active ARsv in CRPC requires full-length androgen receptor. In addition, this study suggests that the increase in the expression ARsv lacking the ligand binding domain expression in CRPC is an acute response to castration, not because of the clonal expansion of castration-resistant cells.
55. Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004; 64:6595-6602. (Pubitemid 39297919)
56. Rocchi P, Beraldi E, Ettinger S, et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 2005; 65:11083-11093. (Pubitemid 41713379)
57. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5:280-285. (Pubitemid 29124362)
58. Raffo AJ, Perlman H, Chen MW, et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55:4438-4445.
59. Miyake H, Nelson C, Rennie PS, Gleave ME. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 2000; 141:2257-2265. (Pubitemid 32274381)
60. Wang L, Hsu CL, Chang C. Androgen receptor corepressors: an overview. Prostate 2005; 63:117-130. (Pubitemid 40525362)
61. Holter E, Kotaja N, Makela S, et al. Inhibition of androgen receptor (AR) function by the reproductive orphan nuclear receptor DAX-1. Mol Endocrinol 2002; 16:515-528. (Pubitemid 34214571)
62. Loy CJ, Sim KS, Yong EL. Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc Natl Acad Sci USA 2003; 100:4562-4567. (Pubitemid 36457770)
63. Gross M, Liu B, Tan J, et al. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 2001; 20:3880-3887. (Pubitemid 32646198)
64. Wafa LA, Cheng H, Plaa N, et al. Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression. Int J Cancer 2011. doi: 10.1002/ijc.26287. [Epub ahead of print]
65. Thomas C, Wafa LA, Lamoureux F, et al. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors. Prostate 2011. doi: 10.1002/pros.21490. [Epub ahead of print]
66. Gao L, Alumkal J. Epigenetic regulation of androgen receptor signaling in prostate cancer. Epigenetics 2010; 5:100-104.
67. Perry AS, Watson RW, Lawler M, Hollywood D. The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol 2010; 7:668-680.
68. Welsbie DS, Xu J, Chen Y, et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009; 69:958-966.
69. Kulp SK, Chen CS, Wang DS, Chen CY. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 2006; 12:5199-5206. (Pubitemid 44453349)
70. Bradley D, Rathkopf D, Dunn R, et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009; 115:5541-5549.
71. Wang LG, Ossowski L, Ferrari AC. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 2004; 23:5175-5184. (Pubitemid 38980350)
72. Karpf AR, Bai S, James SR, et al. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res 2009; 7:523-535.
73. Sonpavde G, Aparicio AM, Zhan F, et al. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer. Urol Oncol 2011; 29:682-689.